Recent studies have implicated heterozygous loss-of-function mutations of CNKSR2 with EAS, which are characterized by seizures, aphasia or the progressive loss of language, attention deficits, and X-linked neurodevelopmental disorders (Polla et al., 2019; Bonardi et al., 2020; Higa et al., 2021; Kang et al., 2021). The gene discussed is CNKSR2; the disease is neurodevelopmental disorder.